Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD

Photo by Haberdoedas / Unsplash

medRxiv Published April 14, 2026 Medically reviewed April 25, 2026 Study authors: Murugadoss, K.; Venkatakrishnan, A.; Gregg, C.; Soundararajan, V. DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider semaglutide dose associations with CVD risk, but note observational limitations.

This observational study used a federated deidentified U.S. electronic health record network to analyze 47,199 patients with baseline cardiovascular disease, a subset of 505,874 semaglutide-treated individuals from a network of 29 million patients. The intervention was semaglutide dose escalation and weight change, compared to metformin, DPP-4 inhibitors, and SGLT2 inhibitors, with follow-up over a 0-2-year landmark period and 2-4-year post-landmark period. Primary outcomes included post-landmark risk of all-cause mortality, composite cardiovascular events, cerebrovascular disease, heart failure, and valvular/rheumatic heart disease.

Main results showed higher maximum semaglutide dose was associated with greater weight loss (3.15% additional weight loss per 1 mg increase, P<0.001) and lower post-landmark risks: all-cause mortality (RR 0.42, p<0.001), composite cardiovascular events (RR 0.51, p<0.001), cerebrovascular disease (RR 0.50, p<0.001), heart failure (RR 0.55, p<0.001), and valvular/rheumatic heart disease (RR 0.71, p=0.025). However, greater achieved weight loss did not show a consistent monotonic association with lower post-landmark cardiovascular risk (p-values 0.14 for mortality and 0.55 for composite endpoint). In the landmark period, semaglutide was associated with lower cardiovascular events than comparators, but effect sizes and absolute numbers were not reported.

Safety and tolerability data were not reported. A key limitation is that whether longer-term cardiovascular benefit tracks achieved weight loss or therapeutic exposure levels remains unclear. The study suggests semaglutide cardiovascular benefit appears organized more by maximum dose attained than by achieved weight-loss magnitude, but practice relevance is restrained due to the observational design, which precludes causal inferences and may involve unmeasured confounders.

Study Details

Sample sizen = 47,199

EvidenceLevel 5

PublishedApr 2026

View Original Abstract ↓

Semaglutide is often optimized for weight loss, but whether longer-term cardiovascular benefit tracks achieved weight loss or therapeutic exposure levels remains unclear. Using a federated deidentified U.S. electronic health record network of 29 million patients, including 505,874 semaglutide-treated individuals, we leveraged multimodal AI technologies to analyze 47,199 patients with baseline cardiovascular disease. We quantified dose escalation and weight change during the 0-2-year period after semaglutide initiation (landmark period) and assessed cardiovascular outcomes during the 2-4-year period (post-landmark). In propensity-matched comparisons during the landmark period, semaglutide was associated with lower cardiovascular events than metformin, DPP-4 and SGLT2 inhibitors. Higher maximum semaglutide dose was associated with greater weight loss during the landmark period (3.15% additional weight loss per 1 mg increase; r=0.97, P<0.001), and lower post-landmark risk of all-cause mortality (RR 0.42, p<0.001), composite cardiovascular events (death, myocardial infarction, or stroke; RR 0.51, p<0.001), cerebrovascular disease (RR 0.50, p<0.001), heart failure (RR 0.55, p<0.001), and valvular/rheumatic heart disease (RR 0.71, p=0.025). In contrast, greater achieved weight loss during the landmark period did not show a consistent monotonic association with lower post-landmark cardiovascular risk (All-cause mortality p-value=0.14, composite cardiovascular endpoint p-value=0.55). Integrating insights from a single cell GLP1R expression atlas was used to infer how semaglutide pharmacology may tie into heart-specific signaling, beyond what is reflected by body-weight reduction alone. The strongest prevalence-weighted GLP1R signal was observed in the pancreas, followed by the heart, where GLP1R engagement potential (GEP) was considerable across cardiomyocyte, cardiac endothelial, and rarer immune cell populations. Together, semaglutide cardiovascular benefit appears organized more by maximum dose attained than by achieved weight-loss magnitude, setting the stage for beyond-obesity trial designs that integrate whole-body spatial intelligence.